Edwards Lifesciences: Transcatheter Plan Remains On Track
This article was originally published in The Gray Sheet
Executive SummaryEdwards Lifesciences' European sales of its next-generation Sapien XT transcatheter aortic heart valve are now the firm's biggest growth engine, but most eyes are fixed on progress toward introducing a first-generation device on the U.S. market next year.
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.